EC Number   |
Expression |
Reference |
|---|
    5.1.99.4 | down |
AMACR is negative in postatrophic hyperplasia, mucinous metaplasia, and urothelial metaplasia |
701605 |
| 5.1.99.4 | down |
decreasing alpha-methylacyl-CoA racemase expression in tumors with less sebaceous differentiation, these findings provide insight into the potential pathogenesis of sebaceous neoplasms while assisting in the microscopic distinction of sebaceous adenoma from sebaceous carcinoma |
704836 |
| 5.1.99.4 | down |
partial atrophy shows negative and weak expression of alpha-methylacyl coenzyme A racemase in 75.3% and 24.7% acini, the secretory compartment in all variants of complete atrophy shows alpha-methylacyl coenzyme A racemase negative expression |
701689 |
| 5.1.99.4 | down |
patients with benign prostate hyperplasia have negative expression of AMACR |
703387 |
| 5.1.99.4 | down |
presence of trifluoroibuprofen induces down-modulation of AMACR expression, suppression of the survival Akt/mTOR signalling pathway and down-modulation of cyclin D1 and survivin with G2/M arrest and apoptosis |
746761 |
| 5.1.99.4 | more |
coexpression of alpha-methylacyl coenzyme A racemase and nuclear p53 in neoplastic lesions |
703973 |
| 5.1.99.4 | up |
AMACR is overexpressed in prostate cancer |
701605 |
| 5.1.99.4 | up |
enzyme is over-expressed in prostate and other cancers |
706046 |
| 5.1.99.4 | up |
enzyme is strongly expressed in prostate cancer cell lines and tissues as compared with benign or normal prostate tissues, furthermore, enzyme is expressed abundantly in colorectal cancer, lung cancer tissues, renal and hepatic cancer, whereas it is barely detected in benign tissues and normal prostate epithelial cells |
705416 |
| 5.1.99.4 | up |
in addition to the over-expression in prostate carcinoma, enzyme is also over-expressed in a number of adenocarcinomas, notably colorectal carcinoma as well as in hepatocellular and renal cell carcinoma |
703387 |
